NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Nintedanib for treating idiopathic pulmonary fibrosis [ID752]

Consultees	Commentators (no right to submit or appeal)
Company	General
Boehringer Ingelheim (nintedanib)	Allied Health Professionals Federation
	 Board of Community Health Councils in
Patient/carer groups	Wales
Action for Pulmonary Fibrosis	 British National Formulary
Afiya Trust	 Care Quality Commission
Black Health Agency	 Department of Health, Social Services
Equalities National Council	and Public Safety for Northern Ireland
Muslim Council of Britain	 Healthcare Improvement Scotland
Muslim Health Network	 Medicines and Healthcare products
 Pulmonary Fibrosis Trust 	Regulatory Agency
South Asian Health Foundation	 National Association of Primary Care
Specialised Healthcare Alliance	 National Pharmacy Association
	NHS Alliance
Professional groups	 NHS Commercial Medicines Unit
Association for Respiratory	 NHS Confederation
Technology and Physiology	 Scottish Medicines Consortium
Association of Respiratory Nurse	
Specialists	Comparator company
British Geriatrics Society	 Roche Products (pirfenidone)
British Thoracic Society	
Primary Care Respiratory Society	Relevant research groups
Royal College of General Practitioners	Breathing Matters
Royal College of Nursing	British Association for Lung Research
Royal College of Pathologists	Cochrane Airways Group
Royal College of Physicians	Health Research Authority
Royal Pharmaceutical Society	MRC Clinical Trials Unit
Royal Society of Medicine –	 National Institute for Health Research
Intellectual Disabilities Forum	Evidence Beview Creen
UK Clinical Pharmacy Association	Evidence Review Group
Othora	Southampton Health Technology Assessment Centre (SUTAC)
Others	Assessment Centre (SHTAC),
Department of Health NUC France d	University of SouthamptonNational Institute for Health Research
NHS England NHS National City CCC	
NHS Nottingham City CCG	Health Technology Assessment Programme
NHS Merton CCG	i Togramme
vveisn Government	Associated Guideline groups
Welsh Government	Associated Guideline groups

National Institute for Health and Care Excellence

Final matrix for the technology appraisal of nintedanib for treating idiopathic pulmonary fibrosis Issue date: February 2015 Page 1 of 3

Appendix C

Consultees	Commentators (no right to submit or appeal)
	 National Clinical Guidelines Centre Associated Public Health groups Public Health England Public Health Wales

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

_

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.